Page 2,729«..1020..2,7282,7292,7302,731..2,7402,750..»

Study links carcinogens to cancer stem cells — but spinach can help

Posted: June 21, 2012 at 12:18 am

Public release date: 20-Jun-2012 [ | E-mail | Share ]

Contact: Rod Dashwood rod.dashwood@oregonstate.edu 541-737-8101 Oregon State University

CORVALLIS, Ore. Researchers at Oregon State University for the first time have traced the actions of a known carcinogen in cooked meat to its complex biological effects on microRNA and cancer stem cells.

The findings are part of a growing awareness of the role of epigenetics in cancer, or the ways in which gene expression and cell behavior can be changed even though DNA sequence information is unaltered.

The scientists also found that consumption of spinach can partially offset the damaging effects of the carcinogen. In tests with laboratory animals, it cut the incidence of colon tumors almost in half, from 58 percent to 32 percent.

The research at OSU's Linus Pauling Institute was recently reported in the journal Molecular Nutrition and Food Research, in work supported by the National Institutes of Health.

"Cancer development is a complex, multi-step process, with damaged cells arising through various means," said Mansi Parasramka, a postdoctoral scholar with LPI. "This study showed that alterations of microRNAs affect cancer stem cell markers in colon cancer formation.

"MicroRNAs are very small factors that do very big things in cells," she said.

Traditionally, cancer was thought to be caused by changes in DNA sequence, or mutations, that allowed for uncontrolled cell growth. That's still true. However, there's also increasing interest in the role played by epigenetics, in which such factors as diet, environmental toxins, and lifestyle affect the expression of genes not just in cancer, but also cardiovascular disease, diabetes, and neurological disorders.

Included in this epigenetic equation is the formation of microRNAs once thought to be "junk DNA" - which researchers were at a loss to understand. It's now known that they influence which areas of DNA get expressed or silenced.

Continue reading here:
Study links carcinogens to cancer stem cells -- but spinach can help

Posted in Stem Cell Videos | Comments Off on Study links carcinogens to cancer stem cells — but spinach can help

Researchers, with Stem Cells, Advance Understanding of Spinal Muscular Atrophy

Posted: June 21, 2012 at 12:18 am

Newswise LOS ANGELES (June 19, 2012) Cedars-Sinais Regenerative Medicine Institute has pioneered research on how motor-neuron cell-death occurs in patients with spinal muscular atrophy, offering an important clue in identifying potential medicines to treat this leading genetic cause of death in infants and toddlers.

The study, published in the June 19 online issue of PLoS ONE, extends the institutes work to employ pluripotent stem cells to find a pharmaceutical treatment for spinal muscular atrophy or SMA, a genetic neuromuscular disease characterized by muscle atrophy and weakness.

With this new understanding of how motor neurons die in spinal muscular atrophy patients, we are an important step closer to identifying drugs that may reverse or prevent that process, said Clive Svendsen, PhD, director of the Cedars-Sinai Regenerative Medicine Institute.

Svendsen and his team have investigated this disease for some time now. In 2009, Nature published a study by Svendsen and his colleagues detailing how skin cells taken from a patient with the disorder were used to generate neurons of the same genetic makeup and characteristics of those affected in the disorder; this created a disease-in-a-dish that could serve as a model for discovering new drugs.

As the disease is unique to humans, previous methods to employ this approach had been unreliable in predicting how it occurs in humans. In the research published in PLoS ONE, to the team reproduced this model with skin cells from multiple patients, taking them back in time to a pluripotent stem cell state (iPS cells), and then driving them forward to study the diseased patient-specific motor neurons.

Children born with this disorder have a genetic mutation that doesnt allow their motor neurons to manufacture a critical protein necessary for them to survive. The study found these cells die through apoptosis the same form of cell death that occurs when the body eliminates old, unnecessary as well as unhealthy cells. As motor neuron cell death progresses, children with the disease experience increasing paralysis and eventually death. There is no effective treatment now for this disease. An estimated one in 35 to one in 60 people are carriers and about in 100,000 newborns have the condition.

Now we are taking these motor neurons (from multiple children with the disease and in their pluripotent state) and screening compounds that can rescue these cells and create the protein necessary for them to survive, said Dhruv Sareen, director of Cedars-Sinais Induced Pluripotent Stem Cell Core Facility and a primary author on the study. This study is an important stepping stone to guide us toward the right kinds of compounds that we hope will be effective in the model and then be reproduced in clinical trials.

The study was funded in part by a $1.9 million Tools and Technology grant from the California Institute for Regenerative Medicine aimed at developing new tools and technologies to aid pharmaceutical discoveries for this disease.

# # #

See the rest here:
Researchers, with Stem Cells, Advance Understanding of Spinal Muscular Atrophy

Posted in Stem Cell Videos | Comments Off on Researchers, with Stem Cells, Advance Understanding of Spinal Muscular Atrophy

Anchoring points determine fate of stem cells

Posted: June 21, 2012 at 12:18 am

Mesenchymal Stem Cells (hMSCs) cultured on a Polyacrylamide gel for 7 days: Cells stained in blue are ALP positive which is a marker for osteogenic differentiation, while the cells that contain red oil droplets underwent adipogenic differentiation. Credit: Bojun Li and Prof. Viola Vogel / ETH Zurich

(Phys.org) -- Researchers were positive: a substrates softness influences the behaviour of stem cells in culture. Now other researchers have made a new discovery: the number of anchoring points to which the cells can adhere is pivotal.

How stem cells differentiate is evidently not so much a question of the stiffness of the substrate upon which they thrive, as the cells mechanical anchoring on the substrate surface. This is shown in a study recently published in Nature Materials by researchers from various European universities, including ETH Zurich.

Since 2006 the research community has been convinced that stem cells can feel the softness of materials they grow upon. Scientists mainly drew this conclusion from correlations between the softness of the substrate and the cells behavior.

The new research project, to which ETH-Zurich professor Viola Vogel and her doctoral student Bojun Li made a key contribution, has come to another conclusion. It reveals that the properties of the network structure of polymers are instrumental in regulating the anchoring of the collagen proteins to which the cells ultimately adhere. And these anchors influence the differentiation of stem cells.

Good protein adhesion makes surface seem stiff

In a series of experiments, which Britta Trappmann from Cambridge University partly conducted at ETH Zurich, the cells were applied to two different polymers of the same softness. However, the polymers differed in terms of their surface structure, which regulates the number of firmly anchored collagen proteins.

If the researchers reduced the number of well-anchored proteins on a hard surface, the cells behaved in the same way as on a soft base. If the anchors were close together, the stem cells differentiated into bone cells. If the anchors were further apart, they became fat cells. The simple correlation that a materials stiffness or elasticity can govern the differentiation of stem cells is therefore not universally valid, says Vogel.

Paradigm shift in cultivation of stem cells

With their experiment, the researchers shake a paradigm. In a study conducted in 2006, scientists revealed a connection between polymer stiffness and the degree of cell differentiation. However, the researchers varied the stiffness of the polymer by varying its network structure.

Continued here:
Anchoring points determine fate of stem cells

Posted in Stem Cell Videos | Comments Off on Anchoring points determine fate of stem cells

Diabetes drug may kill cancer stem cells, study says

Posted: June 21, 2012 at 12:18 am

Results from a new study suggest low doses of the diabetes drug metformin may effectively destroy pancreatic cancer stem cells, reducing the risk of tumor growth or recurrence.

Metformin has previously shown promise in reducing breast cancer risk, after researchers found women who took the drug were 25 percent less likely to develop breast cancer during their lifetimes than women who did not.

This study, conducted in mice, is the first to suggest metformin may actually target the root of certain cancers the tumor-initiating stem cells.

We didnt have any clue regarding the effects of metformin on pancreatic stem cancer cells, study researcher Dr. Christopher Heeschen, professor for experimental medicine at the Spanish National Cancer Research Centre in Madrid, Spain, told FoxNews.com. Its been implied in past studies of pancreatic cancer that patients who use metformin show better outcomes, but there have been no randomized trials yet.

When metformin was combined with a standard chemotherapy to treat pancreatic cancer, the drugs were able to eradicate both cancer stem cells and the differentiated cells that made up the tumor.

Novel strategies for treating pancreatic cancer have to be multi-modal, Heeschen explained. Right now, metformin is used as a second phase treatment, but I could also envision it as a first phase treatment but it has to be in combination with chemotherapy. I dont think the drug alone could wipe out the primary tumor, which is crucial.

In the study, it appeared that metformin merely arrested cancer cell growth in existing tumors, rather than destroying them.

Metformin targets the root of cancer, which has more of an effect on preventing cancer relapse, Heeschen said.

According to Heeschen, researchers are not yet certain as to why metformin appears to have cancer stem cell-killing properties, but from a pragmatic point of view, you see this striking response with a well-established drug thats safe I think its reasonable to move forward with clinical trials, he said.

One clinical trial is already in the recruitment phase, and Heeschen predicted results of the trial would be available by the end of the year.

View post:
Diabetes drug may kill cancer stem cells, study says

Posted in Stem Cell Videos | Comments Off on Diabetes drug may kill cancer stem cells, study says

'Master Molecule' May Improve Stem Cell Treatment of Heart Attacks

Posted: June 21, 2012 at 12:18 am

Newswise Johns Hopkins researchers have discovered that a single protein molecule may hold the key to turning cardiac stem cells into blood vessels or muscle tissue, a finding that may lead to better ways to treat heart attack patients.

Human heart tissue does not heal well after a heart attack, instead forming debilitating scars. For reasons not completely understood, however, stem cells can assist in this repair process by turning into the cells that make up healthy heart tissue, including heart muscle and blood vessels. Recently, doctors elsewhere have reported promising early results in the use of cardiac stem cells to curb the formation of unhealthy scar tissue after a heart attack. But the discovery of a master molecule that guides the destiny of these stem cells could result in even more effective treatments for heart patients, the Johns Hopkins researchers say.

In a study published in the June 5 online edition of the journal Science Signaling, the team reported that tinkering with a protein molecule called p190RhoGAP shaped the development of cardiac stem cells, prodding them to become the building blocks for either blood vessels or heart muscle. The team members said that by altering levels of this protein, they were able to affect the future of these stem cells.

In biology, finding a central regulator like this is like finding a pot of gold, said Andre Levchenko, a biomedical engineering professor and member of the Johns Hopkins Institute for Cell Engineering, who supervised the research effort.

The lead author of the journal article, Kshitiz, a postdoctoral fellow who uses only his first name, said, Our findings greatly enhance our understanding of stem cell biology and suggest innovative new ways to control the behavior of cardiac stem cells before and after they are transplanted into a patient. This discovery could significantly change the way stem cell therapy is administered in heart patients.

Earlier this year, a medical team at Cedars-Sinai Medical Center in Los Angeles reported initial success in reducing scar tissue in heart attack patients after harvesting some of the patients own cardiac stem cells, growing more of these cells in a lab and transfusing them back into the patient.

Using the stem cells from the patients own heart prevented the rejection problems that often occur when tissue is transplanted from another person.

Levchenkos team wanted to figure out what, at the molecular level, causes the stem cells to change into helpful heart tissue. If they could solve this mystery, the researchers hoped the cardiac stem cell technique used by the Los Angeles doctors could be altered to yield even better results.

During their research, the Johns Hopkins team members wondered whether changing the surface where the harvested stem cells grew would affect the cells development. The researchers were surprised to find that growing the cells on a surface whose rigidity resembled that of heart tissue caused the stem cells to grow faster and to form blood vessels. A cell population boom occurred far less often in the stem cells grown in the glass or plastic dishes typically used in biology labs. This result also suggested why formation of cardiac scar tissue, a structure with very different rigidity, can inhibit stem cells naturally residing there from regenerating the heart.

Looking further into this stem cell differentiation, the Johns Hopkins researchers found that the increased cell growth occurred when there was a decrease in the presence of the protein p190RhoGAP.

Excerpt from:
'Master Molecule' May Improve Stem Cell Treatment of Heart Attacks

Posted in Stem Cell Treatments | Comments Off on 'Master Molecule' May Improve Stem Cell Treatment of Heart Attacks

CBR – World's Largest Stem Cell Bank – Applies Two Decades of Experience to Advance Regenerative Medicine

Posted: June 21, 2012 at 12:18 am

SAN BRUNO, Calif., June 20, 2012 /PRNewswire/ -- Twenty years ago this month, CBR (Cord Blood Registry) in partnership with the University of Arizona, processed the first cord blood stem cell sample in the world to be stored specifically for family use. Since 1992, the number of conditions treated with cord blood stem cells has greatly expanded, and so has CBR. Today, CBR is the largest family cord blood bank in the world with more than 425,000 samples in storage a population the size of a major city like Miami. What distinguishes the "city of individuals" with newborn stem cells banked at CBR is the exclusive opportunity to participate in a growing number of ground-breaking clinical trials.

(Photo: http://photos.prnewswire.com/prnh/20120620/SF27549-INFO)

(Logo: http://photos.prnewswire.com/prnh/20120216/AQ54476LOGO)

"As the leader and innovator in family banking, we believe every newborn deserves a healthy future and that we have a responsibility to lead the way," said Heather Brown, vice president of scientific & medical affairs at CBR. "Looking back, the creation of our bank allowed families for the first time to preserve a genetically-related source of newborn stem cells, ready and available if needed for a lifesaving transplant to regenerate a person's immune system after radiation or chemotherapy. As we look to the future, we are helping shape new areas of regenerative medicine. We are the only family bank actively pioneering clinical trials evaluating new therapeutic uses of cord blood stem cells for unexpected injuries and conditions with no current cure."

Expanding Areas of Clinical Research: Helping the Body Heal Injured Nerves Until very recently, the prevailing medical opinion in neurology has been that damage to the central nervous system caused by injuries like birth trauma, accidents or stroke is often permanent. Currently, intervention after injury focuses on stabilizing the patient to minimize damage. However, data from animal research in recent years has challenged this assumption, leading to cord blood stem cell clinical research to study whether these cells may stimulate neural cell and tissue repair to restore function and alleviate neurological impairments.

CBR is taking the lead in moving animal research rapidly into the clinic to investigate the ability for cord blood stem cells to trigger the body's own mechanisms to initiate nerve repair by establishing specific clinical trials at leading medical institutions across the country. By pairing researchers with children who have been diagnosed with chronic conditions like cerebral palsy, traumatic brain injury or hearing loss-- and who also have access to their own cord blood stem cells -- CBR is helping physicians move beyond surgery and drugs to evaluate how newborn stem cells may help the body repair itself.

Celebrating a History of Firsts Throughout its history, CBR has taken many of the first steps to create and advance the notion of preserving and ensuring access to high quality newborn stem cells that are viable for use. Among the company's contributions to stem cell medicine and science, CBR was:

"CBR continuously improves our systems and technology to maintain the highest published cell recovery rate in the industry of 99%, every single time. We treat every sample as if it belongs to our own child or grandchild," says Tom Moore, CEO and founder of CBR. "That care and precision is what we offer clinical researchers, who are partnering exclusively with CBR to evaluate the use of a child's own cord blood stem cells to help treat chronic diseases like cerebral palsy, hearing loss and traumatic brain injury."

About Cord Blood RegistryCBR (Cord Blood Registry) is the world's largest and most experienced cord blood bank.The company has consistently led the industry in technical innovations and safeguards more than 425,000 cord blood collections for individuals and their families. CBR was the first family bank accredited by AABB and the company's quality standards have been recognized through ISO 9001:2008 certificationthe global business standard for quality. CBR has also released more client cord blood units for specific therapeutic use than any other family cord blood bank. Our research and development efforts are focused on helping the world's leading clinical researchers advance regenerative medical therapies.For more information, visit http://www.cordblood.com.

Continue reading here:
CBR - World's Largest Stem Cell Bank - Applies Two Decades of Experience to Advance Regenerative Medicine

Posted in Stem Cell Research | Comments Off on CBR – World's Largest Stem Cell Bank – Applies Two Decades of Experience to Advance Regenerative Medicine

LIFE Focuses on Stem Cell Research – Analyst Blog

Posted: June 21, 2012 at 12:18 am

Referenced Stocks: ILMN, LIFE, TMO

Given the recent flurry of activities, it seems that Life Technologies Corporation ( LIFE ) is focused on strengthening its foothold in the field of stem cell research. The company recently signed a non-exclusive agreement with iPS Academia of Japan for its induced pluripotent stem (iPS) cell patent portfolio. Based on this agreement, the company will be able to expand its portfolio for the iPS cell research community.

Besides, it is well placed to create iPS cells and differentiate them into various cell types to be used in drug discovery and pre-clinical research. The license also enables Life Technologies to provide creation, differentiation and screening services of iPS cell to scientists globally. We consider the agreement to be a significant achievement for the company in the field of stem cell research as iPS cells are gaining attention for use in the areas of drug discovery, disease research and other areas of biotechnology.

The agreement with iPS Academia of Japan comes on the heels of the partnership with Cellular Dynamics International, the world's largest producer of human cells derived from iPS cells. The partnership will aim at commercializing a set of three new products optimized to consistently develop and grow human iPS cells for both research and bioproduction.

These initiatives undertaken by Life Technologies should strengthen its Research Consumables segment. This segment includes molecular and cell biology reagents, endpoint PCR and other benchtop instruments and consumables. These products include RNAi, DNA synthesis, sample prep, transfection, cloning and protein expression profiling and protein analysis, cell culture media used in research, stem cells and related tools, cellular imaging products, antibodies and cell therapy related products. In the most recent quarter, this division recorded a 4% year-over-year increase in revenues to $420 million on the back of growth in cell culture workflow products, endpoint PCR products and molecular and cell biology consumables.

Life Technologies enjoys a strong position in the life sciences market, though management prefers to maintain a cautious but optimistic outlook for the remainder of the year. We are encouraged by the improvement in margins amidst the tight competitive scenario with the presence of players such as Thermo Fisher Scientific ( TMO ), Illumina ( ILMN ), among others.

We have a Neutral recommendation on Life Technologies. The stock retains a Zacks #3 Rank (hold) in the short term.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

View post:
LIFE Focuses on Stem Cell Research - Analyst Blog

Posted in Stem Cell Research | Comments Off on LIFE Focuses on Stem Cell Research – Analyst Blog

LIFE Focuses on Stem Cell Research

Posted: June 21, 2012 at 12:18 am

Given the recent flurry of activities, it seems that Life Technologies Corporation (LIFE) is focused on strengthening its foothold in the field of stem cell research. The company recently signed a non-exclusive agreement with iPS Academia of Japan for its induced pluripotent stem (iPS) cell patent portfolio. Based on this agreement, the company will be able to expand its portfolio for the iPS cell research community.

Besides, it is well placed to create iPS cells and differentiate them into various cell types to be used in drug discovery and pre-clinical research. The license also enables Life Technologies to provide creation, differentiation and screening services of iPS cell to scientists globally. We consider the agreement to be a significant achievement for the company in the field of stem cell research as iPS cells are gaining attention for use in the areas of drug discovery, disease research and other areas of biotechnology.

The agreement with iPS Academia of Japan comes on the heels of the partnership with Cellular Dynamics International, the world's largest producer of human cells derived from iPS cells. The partnership will aim at commercializing a set of three new products optimized to consistently develop and grow human iPS cells for both research and bioproduction.

These initiatives undertaken by Life Technologies should strengthen its Research Consumables segment. This segment includes molecular and cell biology reagents, endpoint PCR and other benchtop instruments and consumables. These products include RNAi, DNA synthesis, sample prep, transfection, cloning and protein expression profiling and protein analysis, cell culture media used in research, stem cells and related tools, cellular imaging products, antibodies and cell therapy related products. In the most recent quarter, this division recorded a 4% year-over-year increase in revenues to $420 million on the back of growth in cell culture workflow products, endpoint PCR products and molecular and cell biology consumables.

Life Technologies enjoys a strong position in the life sciences market, though management prefers to maintain a cautious but optimistic outlook for the remainder of the year. We are encouraged by the improvement in margins amidst the tight competitive scenario with the presence of players such as Thermo Fisher Scientific (TMO), Illumina (ILMN), among others.

We have a Neutral recommendation on Life Technologies. The stock retains a Zacks #3 Rank (hold) in the short term.

Read the Full Research Report on TMO

Read the Full Research Report on ILMN

Zacks Investment Research

More From Zacks.com

See more here:
LIFE Focuses on Stem Cell Research

Posted in Stem Cell Research | Comments Off on LIFE Focuses on Stem Cell Research

Anchoring points determine fate of stem cells

Posted: June 20, 2012 at 3:13 pm

Mesenchymal Stem Cells (hMSCs) cultured on a Polyacrylamide gel for 7 days: Cells stained in blue are ALP positive which is a marker for osteogenic differentiation, while the cells that contain red oil droplets underwent adipogenic differentiation. Credit: Bojun Li and Prof. Viola Vogel / ETH Zurich

(Phys.org) -- Researchers were positive: a substrates softness influences the behaviour of stem cells in culture. Now other researchers have made a new discovery: the number of anchoring points to which the cells can adhere is pivotal.

How stem cells differentiate is evidently not so much a question of the stiffness of the substrate upon which they thrive, as the cells mechanical anchoring on the substrate surface. This is shown in a study recently published in Nature Materials by researchers from various European universities, including ETH Zurich.

Since 2006 the research community has been convinced that stem cells can feel the softness of materials they grow upon. Scientists mainly drew this conclusion from correlations between the softness of the substrate and the cells behavior.

The new research project, to which ETH-Zurich professor Viola Vogel and her doctoral student Bojun Li made a key contribution, has come to another conclusion. It reveals that the properties of the network structure of polymers are instrumental in regulating the anchoring of the collagen proteins to which the cells ultimately adhere. And these anchors influence the differentiation of stem cells.

Good protein adhesion makes surface seem stiff

In a series of experiments, which Britta Trappmann from Cambridge University partly conducted at ETH Zurich, the cells were applied to two different polymers of the same softness. However, the polymers differed in terms of their surface structure, which regulates the number of firmly anchored collagen proteins.

If the researchers reduced the number of well-anchored proteins on a hard surface, the cells behaved in the same way as on a soft base. If the anchors were close together, the stem cells differentiated into bone cells. If the anchors were further apart, they became fat cells. The simple correlation that a materials stiffness or elasticity can govern the differentiation of stem cells is therefore not universally valid, says Vogel.

Paradigm shift in cultivation of stem cells

With their experiment, the researchers shake a paradigm. In a study conducted in 2006, scientists revealed a connection between polymer stiffness and the degree of cell differentiation. However, the researchers varied the stiffness of the polymer by varying its network structure.

Read the original here:
Anchoring points determine fate of stem cells

Posted in Stem Cells | Comments Off on Anchoring points determine fate of stem cells

‘Magical State’ Of Embryonic Stem Cells May Help Overcome Hurdles To Therapeutics

Posted: June 20, 2012 at 3:13 pm

Salk researcher's findings suggest a potentially favorable time to harvest stem cells for therapy and may reveal genes crucial to tissue production

With their potential to treat a wide range of diseases and uncover fundamental processes that lead to those diseases, embryonic stem (ES) cells hold great promise for biomedical science. A number of hurdles, both scientific and non-scientific, however, have precluded scientists from reaching the holy grail of using these special cells to treat heart disease, diabetes, Alzheimer's and other diseases.

In a paper published June 13 in Nature, scientists at the Salk Institute for Biological Studies report discovering that ES cells cycle in and out of a "magical state" in the early stages of embryo development, during which a battery of genes essential for cell potency (the ability of a generic cell to differentiate, or develop, into a cell with specialized functions) is activated. This unique condition, called totipotency, gives ES cells their unique ability to turn into any cell type in the body, thus making them attractive therapeutic targets.

"These findings," says senior authorSamuel L. Pfaff, a professor in Salk'sGene Expression Laboratory, "give new insight into the network of genes important to the developmental potential of cells. We've identified a mechanism that resets embryonic stem cells to a more youthful state, where they are more plastic and therefore potentially more useful in therapeutics against disease, injury and aging."

ES cells are like silly putty that can be induced, under the right circumstances, to become specialized cells-for example, skin cells or pancreatic cells-in the body. In the initial stages of development, when an embryo contains as few as five to eight cells, the stem cells are totipotent and can develop into any cell type. After three to five days, the embryo develops into a ball of cells called a blastocyst. At this stage, the stem cells are pluripotent, meaning they can develop into almost any cell type. In order for cells to differentiate, specific genes within the cells must be turned on.

Pfaff and his colleagues performed RNA sequencing (a new technology derived from genome-sequencing to monitor what genes are active) on immature mouse egg cells, called oocytes, and two-cell-stage embryos to identify genes that are turned on just prior to and immediately following fertilization. Pfaff's team discovered a sequence of genes tied to this privileged state of totipotency and noticed that the genes were activated by retroviruses adjacent to the stem cells.

Nearly 8 percent of the human genome is made up of ancient relics of viral infections that occurred in our ancestors, which have been passed from generation to generation but are unable to produce infections. Pfaff and his collaborators found that cells have used some of these viruses as a tool to regulate the on-off switches for their own genes. "Evolution has said, 'We'll make lemonade out of lemons, and use these viruses to our advantage,'" Pfaff says. Using the remains of ancient viruses to turn on hundreds of genes at a specific moment of time in early embryo development gives cells the ability to turn into any type of tissue in the body.

From their observations, the Salk scientists say these viruses are very tightly controlled-they don't know why-and active only during a short window during embryonic development. The researchers identified ES cells in early embryogenesis and then further developed the embryos and cultured them in a laboratory dish. They found that a rare group of special ES cells activated the viral genes, distinguishing them from other ES cells in the dish. By using the retroviruses to their advantage, Pfaff says, these rare cells reverted to a more plastic, youthful state and thus had greater developmental potential.

Pfaff's team also discovered that nearly all ES cells cycle in and out of this privileged form, a feature of ES cells that has been underappreciated by the scientific community, says first author Todd S. Macfarlan, a former postdoctoral researcher in Pfaff's lab who recently accepted a faculty position at the Eunice Kennedy Shriver National Institute of Child Health and Human Development. "If this cycle is prevented from happening," he says, "the full range of cell potential seems to be limited."

It is too early to tell if this "magical state" is an opportune time to harvest ES cells for therapeutic purposes. But, Pfaff adds, by forcing cells into this privileged status, scientists might be able to identify genes to assist in expanding the types of tissue that can be produced.

Go here to see the original:
‘Magical State' Of Embryonic Stem Cells May Help Overcome Hurdles To Therapeutics

Posted in Stem Cells | Comments Off on ‘Magical State’ Of Embryonic Stem Cells May Help Overcome Hurdles To Therapeutics

Page 2,729«..1020..2,7282,7292,7302,731..2,7402,750..»